Rising Number of Surgeries and Chronic and Acute Pain Disorders are Driving the Global Lignocaine Market

Global lignocaine market is anticipated to grow at a considerable CAGR of 6.4% during the forecast period (2024-2031). The increasing number of surgical operations including dental procedures, aesthetic surgery, and plastic surgeries drives the market growth. Additionally, the rise in chronic and acute pain problems throughout the world, and the economic advantages connected with lignocaine hydrochloride, are contributing towards market growth. Lignocaine patches are also available to relieve chronic and acute pain and are the suggested first-line therapy for the treatment of neuropathic pain in elderly patients, and those suffering from shingles, thus boosting the market growth. The global lignocaine market is segmented by dosage form (creams, patches, injectables, others), by application (heart arrhythmia, dental procedure, epilepsy, others), and by geographies (North America, Europe, Asia-Pacific, and Rest of the World).

Lignocaine, commonly known as xylocaine or lidocaine, is a numbing agent used to numb a specific region of tissue (local anesthetic). In addition, it is utilized for nerve blocks and to treat ventricular tachycardia. Lignocaine is offered as a combination with a low amount of adrenaline (epinephrine) to allow for higher numbing dosages, less bleeding, and a longer-lasting numbing effect. It usually starts acting in four minutes and lasts for half an hour to three hours when taken as an injection.  

The major players in the global lignocaine market include Alanza Inc., Amphastar Pharmaceuticals, Inc., Cirondrugs, Mahendra Chemicals, Pfizer Inc., and others. The market players are contributing significantly to the market growth, by the adoption of various business strategies, such as collaborations, mergers and acquisitions, product portfolio diversification, and more.

Browse the full report description of “Global Lignocaine Market Size, Share & Trends Analysis By Dosage Form (Creams, Patches, Injectables, others), By Application (Heart Arrhythmia, Dental Procedure, Epilepsy, others), Forecast (2024-2031)” at https://www.omrglobal.com/industry-reports/lignocaine-market

Recent Developments 

• In February 2024, Scilex Holding Company announced that ZTlido® has reached three major milestones. The milestones include the total number of patients treated reaching 1 million, ZTlido® becoming the number one prescribed non-opioid branded pain medication by pain specialists in the US, and Patients reporting 89% satisfaction with ZTlido®.

• In November 2023, the Perelman School of Medicine at the University of Pennsylvania conducted research showing Lidocaine activates certain bitter taste receptors through two unique mechanisms that result in cancer cell death. 

• In November 2023, Scilex Holding Company announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,793,766, further strengthening the Company’s intellectual property position and coverage for its lead commercial product, ZTlido® (lidocaine topical system) 1.8%.  The Patent, titled ‘Non-aqueous Patch for the Relief of Pain’, covers a method of relieving pain through the application of a lidocaine-containing patch. 

• In October 2023, Hospira, Inc., voluntarily recalled the lots of 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10mL vial; 1% Lidocaine HCl Injection, USP, 50 mg/5mL vial; and 2% Lidocaine HCl Injection, USP, 100 mg/5mL vial to the user level. This was attributed to the potential for the presence of glass particulate matter, in the medication. 

• In April 2023, FFF Enterprises Inc. announced that it entered a partnership with Sintetica® US, to provide Lidocaine Hydrochloride Injection, a short-acting amide-type local or regional anesthetic.

• In February 2023, GHA restricted the use of Lidocaine Patches to two conditions. The medicine has been approved for PHN. The patches were used in Gibraltar for many other conditions, for which they cannot be endorsed for use. The use of the drug for low back pain, and musculoskeletal pain, does not have enough supporting evidence, to justify its continued usage. 

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/lignocaine-market